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Introduction: The phase 3 MONET1 study evaluated motesanib (a 
small-molecule inhibitor of vascular endothelial growth factor recep-
tors) plus carboplatin/paclitaxel versus placebo plus carboplatin/
paclitaxel as first-line therapy for advanced non–small-cell lung can-
cer (NSCLC). Treatment and enrollment of patients with squamous 
histology were permanently discontinued following higher early 
mortality and gross hemoptysis in those with squamous NSCLC 
who received motesanib. Enrollment of patients with nonsquamous 
histology was temporarily halted, but resumed following a protocol 
amendment (Scagliotti et al. J Clin Oncol. 2012;30:2829–2836). 
Herein, we report data from the squamous cohort.
Methods: Patients with stage IIIB/IV or recurrent squamous NSCLC 
(without prior systemic therapy for advanced disease) received up 
to six 3-week cycles of chemotherapy (carboplatin, area under the 
curve 6 mg/mL•min/paclitaxel, 200 mg/m2) and were randomized 1:1 
to receive motesanib 125 mg (Arm A) or placebo (Arm B) once daily. 
The primary end point was overall survival.
Results: Three-hundred and sixty patients with squamous NSCLC 
were randomized (Arm A, n = 182; Arm B, n = 178) between July 
2007 and November 2008. Twenty-three patients (13%) in Arm A 
and 10 (6%) in Arm B had fatal adverse events within the first 60 
days of treatment. Among these, six patients in Arm A, but none in 
Arm B, had fatal bleeding events. At final analysis, serious adverse 
events had occurred in 47% of patients in Arm A and 29% of patients 
in Arm B. Median overall survival was similar in Arms A and B (11.1 
versus 10.7 months).
Conclusions: Motesanib plus carboplatin/paclitaxel had unaccept-
able toxicity compared with carboplatin/paclitaxel alone in patients 
with advanced squamous NSCLC.
Key Words: Squamous histology, NSCLC, Motesanib, Carboplatin, 
Paclitaxel
(J Thorac Oncol. 2014;9: 1154–1161)
For patients with squamous cell carcinoma of the lung, two-drug chemotherapy regimens (including carbopla-
tin/paclitaxel [C/P]) are a cornerstone of current treatment 
options.1,2 However, outcomes associated with conventional 
therapies remain poor,3 underlining the clear need for alterna-
tive approaches to treatment in this patient population. Some 
studies have evaluated combinations of targeted therapies plus 
standard-of-care chemotherapy in this setting. At present only 
one study that enrolled patients with squamous histology as 
part of a larger study in advanced non–small-cell lung can-
cer (NSCLC; 377 of 1125 patients; 34%) has demonstrated an 
overall survival (OS) benefit.4 That study (FLEX) investigated 
the addition of cetuximab to cisplatin/vinorelbine and showed 
an OS improvement of 1.2 months compared with cisplatin/
vinorelbine alone in an open-label, randomized phase 3 trial 
in patients with NSCLC.4
Angiogenesis is required for the development and 
progression of solid tumors, including NSCLC.5 Signaling 
through the vascular endothelial growth factor (VEGF) path-
way has been shown to play a central role in the angiogenic 
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processes that contribute to the development, growth, and 
metastasis of NSCLC.6 To date, bevacizumab, a monoclo-
nal anti-VEGF antibody, is the only angiogenesis inhibitor 
that has been shown to improve OS7 and progression-free 
survival (PFS)7–9 as first-line therapy in combination with 
chemotherapy in patients with nonsquamous NSCLC. 
Bevacizumab is contraindicated for patients with squamous 
NSCLC because the combination of bevacizumab plus C/P 
was associated with a high incidence of severe hemorrhage 
among patients with squamous histology in a phase 2 study.10 
Tyrosine kinase inhibitors of the VEGF pathway, such as 
vandetanib,11 cediranib,12 and sorafenib,13,14 that have been 
evaluated as first-line treatment in patients with NSCLC of 
all or selected lung cancer histologies have failed to show a 
survival benefit. Those studies that also enrolled and treated 
patients with squamous NSCLC (between 18% and 24% of 
the total enrolled patient populations with NSCLC) did not 
provide sufficient evidence in support of a positive risk-ben-
efit profile.11–13
Motesanib is an oral, small-molecule inhibitor of 
VEGF receptors 1, 2, and 3; Kit; and platelet-derived growth 
factor receptor (PDGFR)15 that has demonstrated antitumor 
activity in histologically diverse xenograft models of lung 
cancer16 and in patients with a variety of solid tumors.17–20 
In the randomized phase 3 MONET1 study, which enrolled 
patients between July 5, 2007, and March 18, 2010, mote-
sanib plus C/P, compared with placebo plus C/P, did not sig-
nificantly improve OS in patients with nonsquamous NSCLC 
(N = 1090).21 Initially, MONET1 enrolled patients with both 
nonsquamous and squamous histology. After higher rates 
of early mortality and gross hemoptysis emerged in the 
MONET1 study among patients with squamous histology 
randomized to motesanib, the study was temporarily stopped 
and subsequently amended to allow continued enrollment of 
patients with nonsquamous NSCLC only.21 Before the study 
stop, a total of 354 patients with squamous NSCLC histol-
ogy had received at least one dose of motesanib (n = 180) or 
placebo (n = 174). Herein, we report detailed early and over-
all toxicity data along with clinical outcomes in this patient 
cohort, one of the largest to date with the NSCLC squamous 
cell histologic subtype that has been recruited to a first-line 
randomized trial.
METHODS
Eligibility
All patients provided written informed consent and the 
study protocol was approved by an independent ethics com-
mittee or institutional review board at each study site. Eligible 
patients were at least 18 years of age and had histologically 
confirmed unresectable stage IIIB with pericardial/pleural 
effusion or stage IV/recurrent NSCLC and measurable or non-
measurable disease per Response Evaluation Criteria in Solid 
Tumors (RECIST) version 1.0.22 Key exclusion criteria were 
life expectancy less than 3 months; an Eastern Cooperative 
Oncology Group performance status greater than or equal to 
2; untreated or symptomatic central nervous system metas-
tases; prior chemotherapy, including adjuvant chemotherapy 
within 52 weeks of randomization; prior targeted therapy; 
central or peripheral radiation within 28 or 14 days, respec-
tively; arterial or venous thrombosis within 12 months; pul-
monary hemorrhage or gross hemoptysis within 6 months of 
randomization; bleeding diathesis or bleeding within 14 days; 
uncontrolled hypertension (defined as resting blood pressure 
>150/90 mmHg; antihypertensive medications were allowed 
if the patient was stable on their current dose at the time of 
randomization); and inadequate renal cardiac, hepatic, or 
hematologic function.
Study Design and Treatments
This phase 3, randomized, placebo-controlled, double-
blind study was conducted at 198 centers in 32 countries.21 
Using a computerized interactive voice response system, 
patients were randomized 1:1 to receive either motesanib 
125 mg once daily (Arm A) or placebo (Arm B). All patients 
also received chemotherapy (carboplatin, [area under the 
curve 6 mg/mL·min]/paclitaxel, 200 mg/m2) beginning on 
day 1 of each 3-week cycle up to a maximum of six cycles. 
Randomization was stratified by the following factors: his-
tology (nonsquamous versus squamous), disease stage (IIIB 
versus IV/recurrent), weight loss in the 6 months before ran-
domization (<5% versus ≥5%), sex (male versus female), and 
prior adjuvant chemotherapy (yes versus no).
Treatment was planned to continue until patients experi-
enced disease progression, had unacceptable toxicity, or with-
drew consent, for a maximum of 36 months. Modifications 
of doses and treatment discontinuations followed the rules 
reported previously.21 Specifically, if grade ≥2 bleeding or 
hemoptysis occurred, motesanib/placebo was permanently 
discontinued. For other grade 3/4 treatment-related toxicities, 
motesanib/placebo was withheld until the toxicity resolved to 
grade ≤1 or baseline. If the toxicity resolved, treatment could 
be resumed with a 25-mg dose reduction; all dose reduc-
tions were permanent. Motesanib/placebo was discontinued 
permanently if more than two dose reductions were required, 
grade 3/4 toxicity recurred after a dose delay and/or reduc-
tion, or grade 3/4 toxicity persisted for more than 3 weeks.
Study Protocol Amendment
In November 2008, the study’s independent data mon-
itoring committee reviewed data from the first 600 patients 
enrolled, including 223 patients with squamous histology. 
The committee recommended that enrollment of all patients 
be stopped and that treatment of patients with squamous 
NSCLC be discontinued because the data indicated a higher 
early mortality and a higher event rate of gross hemopty-
sis in those patients with squamous histology who received 
motesanib compared with placebo.21 Patients with squa-
mous NSCLC immediately discontinued blinded treatment 
with motesanib and placebo, but continued to receive up 
to six cycles of C/P per protocol. Patients also continued 
their study visits (every 3 weeks) and radiological imaging 
(as described below) to assess disease status. Enrollment 
of patients with nonsquamous NSCLC was subsequently 
reinstated.21
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Study End Points
The primary end point was OS (time from randomiza-
tion to death). Secondary endpoints included PFS (time from 
randomization to disease progression per RECIST, or death 
from any cause); objective response rate (ORR) per RECIST,22 
and incidence of treatment-emergent adverse events (AEs).
Assessments
Tumor assessments were performed by computed 
tomography/magnetic resonance imaging every 6 ± 1 weeks. 
Tumor response was evaluated by investigators according to 
RECIST version 1.0.22 Objective responses were required to 
be confirmed ≥4 weeks after the initial assessment of response.
AEs occurring during the study (study day 1–30 days 
after the last dose) were recorded and classified in accordance 
with the National Cancer Institute Common Terminology 
Criteria for Adverse Events version 3.0.23 Serious AEs were 
defined as AEs that were fatal, life threatening, required hos-
pitalization or prolongation of hospitalization, or resulted in 
significant disability/incapacity or other medical hazard.
Statistical Analysis
The MONET1 study was originally designed to enroll 
approximately 1240 patients (all histologies). All analyses 
of outcomes in the squamous patient population are descrip-
tive only and not intended to allow statistical inference. The 
squamous analysis set included all patients randomized under 
the squamous stratification or with a squamous component 
(squamous, adenosquamous, or mixed histology) noted on the 
case report form at baseline. Cox proportional hazard mod-
els were used to estimate hazard ratios (HRs) for the treat-
ment effect of motesanib versus placebo on OS and PFS.24 
Comparisons of OS and PFS between Arms A and B were 
performed using log-rank tests stratified by the randomiza-
tion stratification factors. Differences in ORR between Arms 
A and B were evaluated using a Cochran-Mantel-Haenszel 
test stratified by the randomization stratification factors. 
Analyses of OS and PFS included all randomized patients 
with squamous histology per the intent-to-treat principle. The 
analysis of ORR included all patients with measurable dis-
ease at baseline. Interim and final safety analyses included all 
randomized patients with squamous histology who received 
at least one dose of motesanib or placebo.
RESULTS
Demographics and Baseline Characteristics
Between July 5, 2007, and November 14, 2008, 360 
patients with squamous histology were randomized to receive 
motesanib (n = 182; Arm A) or placebo (n = 178; Arm B) 
(Fig. 1). Six patients did not receive motesanib (n = 2) or pla-
cebo (n = 4). Demographic and clinical characteristics were bal-
anced across the two treatment arms. The majority of patients 
had Eastern Cooperative Oncology Group performance status 
of 1, stage IV/recurrent disease, and weight loss less than 5% 
in the 6 months before randomization (Table 1).
Treatment
The median daily doses of motesanib or placebo admin-
istered were 125 mg in both treatment arms. Patients received 
motesanib for a median of 67 days (range, 1−323 days) and 
placebo for 93 days (range, 2−375 days). Patients in Arm A 
received a median of four cycles (range, one to six cycles) 
of carboplatin; patients in Arm B received a median of six 
cycles (range, one to six cycles). Similarly, patients in Arm 
A received a median of four cycles (range, one to six cycles) 
of paclitaxel, whereas patients in Arm B received a median 
of six cycles (range, one to six cycles). In Arm A, 39% of 
patients completed all 6 cycles of chemotherapy treatment; 
in Arm B, 52% of patients completed treatment. Consistent 
with the data monitoring committee’s recommendation (see 
Methods—Study Amendment), all patients with squamous 
histology had discontinued motesanib/placebo at the time of 
this analysis. The number of patients who discontinued treat-
ment because of the study amendment (i.e., administrative 
decision) was 74 (41%) in Arm A and 72 (40%) in Arm B. 
Patients with squamous NSCLC 
randomized (n=360)
Arm A: Motesanib 125 mg QD + C/P (n=182)
Received motesanib (n=180)
Did not receive motesanib (n=2)
Arm B: Placebo + C/P (n=178)
Received placebo (n=174)
Did not receive placebo (n=4)
Ongoing (n=0)
Discontinued motesanib (n=180)
Administrative decision (n=74)
Disease progression (n=39)
Adverse event (n=31)
Death (n=21)
P ti t t ( 6)
Ongoing (n=0)
Discontinued placebo (n=174)
Administrative decision (n=72)
Disease progression (n=71)
Adverse event (n=16)
Death (n=9)   
C t ithd ( 5)a en  reques n=
Consent withdrawn (n=5)
Noncompliance (n=2)
Ineligibility determined (n=1)
Lost to follow-up (n=1)
onsen  w rawn n=
Noncompliance (n=1)
Patient request (n=1)
Analyzed for efficacy 
All d i d ti t ith hi t l ( 182)
Analyzed for efficacy
All d i d ti t ith hi t l ( 178) ran om ze  pa en s w  squamous s o ogy n=
Excluded from efficacy analysis (n=0)
Analyzed for safety (n=181)
Excluded from safety analysis (n=1)
 ran om ze  pa en s w  squamous s o ogy n=
Excluded from efficacy analysis (n=0)
Analyzed for safety (n=173)
Excluded from safety analysis (n=5)
FIGURE 1.  Disposition of patients. 
“Administrative decision” refers to 
the study amendment ( immediate 
 discontinuation of blinded  motesanib/
placebo treatment of patients with 
squamous NSCLC  histology). One 
patient in the  placebo arm received 
at least one dose of motesanib and, 
therefore, was included in the safety 
analysis of the motesanib and not 
the placebo arm. C/P, carboplatin/ 
paclitaxel; NSCLC, non–small-cell  
lung cancer; QD, once daily.
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Study discontinuation as a result of AEs or death was higher 
in Arm A than B (Fig. 1). Median follow-up times were 43.5 
days (range, 1–160 days) in Arm A and 42.5 days (1–163 
days) in Arm B.
Early Toxicity
Twenty-three patients (13%) in Arm A and 10 patients 
(6%) in Arm B had fatal AEs within 60 days of initiating treat-
ment. The most notable AEs with early onset and fatal out-
come were bleeding events, which occurred only in patients 
who received motesanib: five patients in Arm A had grade 5 
pulmonary hemorrhage and one patient had grade 5 hemop-
tysis (no grade 5 bleeding events among patients in Arm B). 
Fatal pulmonary hemorrhage in the motesanib arm devel-
oped as early as 30 days within treatment start (n = 4 patients 
versus n = 0 in the placebo arm). Within 60 days of initi-
ating treatment, five patients in Arm A had grade 5 cardiac 
toxicity (cardiorespiratory arrest, cardiopulmonary failure, 
circulatory collapse, myocardial infarction, and myocardial 
ischemia; n = 1 each) compared with only one patient in Arm 
B (congestive cardiac failure). Fatal AEs that occurred with 
both motesanib and placebo treatment were grade 5 respi-
ratory failure (Arms A/B, n = 2/1), acute respiratory failure 
(n = 1/1), multiorgan failure (n = 1/1), and NSCLC (i.e., 
death due to disease progression; n = 1/1). Two patients in 
Arm B had pneumonia (no events in Arm A).
Serious AEs that emerged during the first 6 months of 
treatment also occurred more frequently in patients in Arm 
A than in patients randomized to Arm B (46% versus 28%; 
Table 2). Specific AEs accounting for this difference in inci-
dence between treatment arms included diarrhea (7% of 
patients in Arm A versus <1% in Arm B),  dehydration 
(5% versus 2%, respectively), and pulmonary hemorrhage 
(3%  versus 0%).
Toxicity Throughout the Study
The incidence of grade 3 AEs, grade 5 AEs, and 
serious AEs throughout the study was also greater among 
patients in Arm A than Arm B; the incidence of grade 4 
AEs was similar across arms (Table 3). Twenty percent of 
patients in Arm A had AEs leading to discontinuation, com-
pared with 10% in Arm B. AEs occurring with an increased 
incidence of at least 5% in Arm A compared with Arm B 
included diarrhea, alopecia, nausea, and vomiting (Table 3). 
Hypertension occurred in 26% of patients in Arm A and 9% 
of patients in Arm B.
Specific serious grade ≥3 hemorrhagic events included 
pulmonary hemorrhage (Arm A, n = 5 versus Arm B, n = 0) 
and hemoptysis (n = 2 versus n = 1, respectively), most of 
which occurred in the early treatment phase (see above); gas-
trointestinal hemorrhage (n = 1 versus n = 0), and gastric 
ulcer hemorrhage (n = 1 versus n = 0). With the exception of 
one event of hemoptysis in Arm A (grade 4) and the gastric 
ulcer hemorrhage (grade 3, Arm A), all serious hemorrhagic 
events on study were grade 5. Serious grade ≥3 gallbladder 
disorders (all grade 3) occurred only in patients in Arm A 
(cholecystitis, n = 2; acute cholecystitis, gallbladder enlarge-
ment, and gallbladder disorder, n = 1 each). The incidence of 
serious grade ≥3 thromboembolic events (all grade 3) was 
similar in Arms A and B (pulmonary embolism, n = 0 and 
n = 1; arterial thrombosis, n = 0 and n = 1; deep vein throm-
bosis, n = 1 and n = 0).
Over the course of the study (i.e., within 30 days of 
their last dose), 37 patients (20%) in Arm A and 21 patients 
(12%) in Arm B had grade 5 AEs. Those that accounted for 
notable differences between treatment arms included NSCLC 
(Arm A, n = 4; Arm B, n = 5), pulmonary hemorrhage (n = 5 
versus n = 0, respectively), pneumonia (n = 0 versus n = 3), 
cardiorespiratory arrest (n = 2 versus n = 1), respiratory fail-
ure (n = 2 versus n = 1), and cardiopulmonary failure (n = 2 
versus n = 0). Additional grade 5 cardiac toxicities reported 
TABLE 1.  Baseline Demographics and Disease Characteristicsa
Arm A  
Motesanib + C/P 
(n = 182)
Arm B  
Placebo + C/P 
(n = 178)
Median age, years (range) 62.0 (31─79) 59.5 (32─81)
Men,b n (%) 145 (80) 150 (84)
ECOG performance status, n (%)
  0 64 (35) 66 (37)
  1 118 (65) 111 (62)
  Missing 0 (0) 1 (<1)
Past or present smoker, n (%) 153 (84) 159 (89)
Race, n (%)
  White 132 (73) 132 (74)
  Asianc 39 (21) 29 (16)
  Hispanic 9 (5) 11 (6)
  Black 1 (<1) 5 (3)
  Other 1 (<1) 1 (<1)
Disease stage at study entry,b n (%)
  Stage IIIB with pericardial/pleural 
effusion
28 (15) 25 (14)
  Stage IV/recurrent 154 (85) 153 (86)
Weight loss <5% in previous  
6 months,b n (%)
139 (76) 136 (76)
Brain metastases,d n (%)
  Yes 9 (5) 9 (5)
  No 172 (95) 169 (95)
  No information available 1 (<1) 0 (0)
Prior adjuvant chemotherapy,b n (%) 2 (1) 3 (2)
Histology, n (%)
  Adenocarcinomae 0 (0) 2 (1)
  Squamous cell carcinoma 174 (96) 173 (97)
  Undifferentiated 1 (<1) 0 (0)
  Otherf 7 (4) 3 (2)
C/P, carboplatin/paclitaxel; ECOG, Eastern Cooperative Oncology Group.
aFor all randomized patients with squamous histology.
bRandomization stratification factors.
cIncludes Japanese patients.
dAll patients with brain metastases had received prior radiotherapy, with the 
exception of one patient in the motesanib arm for whom no radiotherapy was reported.
eAdenocarcinoma with squamous cell components and adenosquamous/
adenocarcinoma, respectively.
fIncludes adenosquamous (n = 6), non-small cell (n = 2), and mixed histology 
(adenocarcinoma with squamous; n = 2).
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included cardiac arrest (n = 1 versus n = 0), myocardial infarc-
tion (n = 1 versus n = 0), myocardial ischemia (n = 1 versus 
n = 0), and congestive cardiac failure (n = 0 versus n = 1).
Efficacy Results
At the time of this analysis, 145 patients in Arm A and 
150 patients in Arm B had died (total, 82%). Median overall 
OS time in Arm A was 11.1 months (95% confidence interval 
[CI], 9.0–12.8 months) compared with 10.7 months (95% CI, 
9.4–12.1 months) in Arm B (HR, 0.89; 95% CI, 0.71–1.12; 
p = 0.3306; Fig. 2A). In Arm A, median 1-year and 2-year sur-
vival rates were 46% and 21%, respectively. In Arm B, median 
1-year and 2-year survival rates were 44% and 12%, respec-
tively. Similarly, 114 patients in Arm A and 121 patients in 
Arm B had had PFS events at the time of this analysis. Median 
PFS times were 4.9 months (95% CI, 4.2–5.6 months) and 5.1 
months (95% CI, 4.4–5.6 months) in Arms A and B, respec-
tively (HR, 0.85; 95% CI, 0.65–1.11; p = 0.2294; Fig. 2B).
Nearly all patients had measurable disease at baseline 
(Table 4). The ORR in Arm A was 38% compared with 35% in 
Arm B (difference, 2.6%: 95% CI, −7.4 to 12.6; p = 0.7362). 
Among patients with a confirmed objective response, the 
duration of response was 7.2 months (95% CI, 4.8–9.1 
months) for patients in Arm A versus 4.4 months (95% CI, 
4.2–5.6 months) for patients in Arm B.
TABLE 2.  Serious Adverse Events Occurring Within 
6 Months of Treatment Initiationa
Arm A  
Motesanib + C/P 
(n = 181)
Arm B  
Placebo + C/P 
(n = 173)
Patients with any serious  
adverse event, n (%)
84 (46) 48 (28)
Any serious adverse event, n (%)b
  Diarrhea 12 (7) 1 (<1)
  Dehydration 9 (5) 3 (2)
  Dyspnea 8 (4) 6 (3)
  Neutropenia 8 (4) 5 (3)
  Anemia 7 (4) 6 (3)
  Pneumonia 6 (3) 9 (5)
  Vomiting 6 (3) 3 (2)
  Febrile neutropenia 5 (3) 1 (<1)
  Hemoptysis 5 (3) 1 (<1)
  Thrombocytopenia 5 (3) 1 (<1)
  Pulmonary hemorrhage 5 (3) 0 (0)
  Asthenia 4 (2) 1 (<1)
  Fatigue 4 (2) 1 (<1)
  Nausea 4 (2) 1 (<1)
  Pleural effusion 4 (2) 0 (0)
  Hypotension 3 (2) 2 (1)
  Abdominal pain 3 (2) 1 (<1)
  Decreased appetite 3 (2) 0 (0)
  Sepsis 3 (2) 0 (0)
  Pyrexia 1 (<1) 3 (2)
C/P, carboplatin/paclitaxel.
aSerious adverse events are reported for all patients with squamous histology who 
received ≥1 dose of motesanib or placebo and include events occurring during treatment 
and within 30 days of the last administration of study treatment.
bIn ≥2% of patients in either treatment arm.
TABLE 3.  Adverse Events Throughout the Studya
Arm A  
Motesanib + C/P 
(n = 181)
Arm B  
Placebo + C/P 
(n = 173)
Patients with any adverse event, n (%) 172 (95) 157 (91)
  Worst grade 3 59 (33) 46 (27)
  Worst grade 4 18 (10) 15 (9)
  Worst grade 5 37 (20) 21 (12)
Adverse events with ≥5% difference in  
incidence between arms, n (%)
  Diarrhea 69 (38) 28 (16)
  Alopecia 62 (34) 70 (40)
  Nausea 50 (28) 37 (21)
  Hypertension 47 (26) 15 (9)
  Vomiting 39 (22) 30 (17)
  Decreased appetite 40 (22) 25 (14)
  Anemia 33 (18) 43 (25)
  Weight decreased 31 (17) 13 (8)
  Thrombocytopenia 27 (15) 14 (8)
  Headache 23 (13) 11 (6)
  Abdominal pain 20 (11) 9 (5)
  Arthralgia 18 (10) 30 (17)
  Dehydration 17 (9) 6 (3)
  Depression 12 (7) 4 (2)
  Chest pain 11 (6) 24 (14)
Patients with serious  
adverse events, n (%)
85 (47) 50 (29)
Serious grade ≥3 adverse  
events in ≥2% of patients  
in either treatment arm
81 (45) 46 (27)
  Diarrhea 9 (5) 0 (0)
  Neutropenia 8 (4) 5 (3)
  Dyspnea 7 (4) 7 (4)
  Dehydration 7 (4) 2 (1)
  Pneumonia 6 (3) 7 (4)
  Pulmonary hemorrhage 5 (3) 0 (0)
  Non–small-cell lung cancerb 5 (3) 4 (2)
  Anemia 4 (2) 4 (2)
  Vomiting 4 (2) 2 (1)
  Febrile neutropenia 4 (2) 1 (<1)
  Pleural effusion 4 (2) 0 (0)
  Abdominal pain 3 (2) 1 (<1)
  Nausea 3 (2) 1 (<1)
  Fatigue 3 (2) 0 (0)
  Decreased appetite 3 (2) 0 (0)
  Sepsis 3 (2) 0 (0)
  Thrombocytopenia 4 (2) 1 (<1)
AE, adverse event; C/P, carboplatin/paclitaxel.
aAEs are reported for all patients with squamous histology who received ≥1 dose of 
motesanib or placebo and include events occurring during treatment and within 30 days 
of the last administration of study treatment.
bPatients with non–small-cell lung cancer reported as an adverse event by investigators.
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DISCUSSION
Although the initial objective of the MONET1 study—
to evaluate motesanib in combination with C/P in patients 
with squamous and nonsquamous NSCLC histology—was not 
achieved, the study has provided one of the largest data sets of 
patients with squamous NSCLC treated with a VEGF recep-
tor inhibitor. The results show early onset of increased risk 
of toxicity, particularly in the incidence of fatal AEs, among 
patients with squamous histology who received motesanib, 
with more than twice as many deaths in the motesanib arm 
(13%) than in the placebo arm (6%) during the first 60 days 
of treatment. The increased risk of early mortality appeared to 
be largely driven by hemorrhagic events: six patients in Arm 
A had grade 5 pulmonary hemorrhage or hemoptysis within 
60 days of initiating treatment (no events occurred in Arm 
B), and four patients in Arm A developed grade 5 pulmonary 
hemorrhage within 30 days of initiating treatment. It appears 
that these toxicities contribute to the early divergence between 
the OS and PFS curves for Arms A and B (Fig. 2). Overall, 
fatal cardiac toxicities were reported more frequently in the 
motesanib arm. The overall incidences of grade ≥3 AEs, fatal 
AEs, serious AEs, and AEs leading to treatment discontinua-
tion were also higher with motesanib compared with placebo. 
AEs accounting for these differences included hemorrhagic 
events, hypertension, gastrointestinal events, and gallblad-
der-related disorders (but not thromboembolic events), all of 
which have been reported in previous studies investigating 
motesanib as a monotherapy and in combination with chemo-
therapy.17,19,20,25–30 Overall, the toxicity profile was consistent 
with earlier reports. Among patients who received placebo, 
the incidence of AEs was broadly consistent with toxicity 
anticipated for patients receiving C/P chemotherapy and with 
toxicity reported for placebo-treated patients in the MONET1 
nonsquamous cohort.3,4,31
Increased risk of bleeding has been reported in some—
but not all—studies evaluating VEGF pathway inhibitors as 
first-line therapy for advanced NSCLC in patient populations 
that included squamous histology. In a phase 2 study, four of 
13 patients with squamous NSCLC and two of 54 patients 
with nonsquamous NSCLC who received bevacizumab plus 
C/P had severe life-threatening hemorrhagic events (none 
occurred in patients who received C/P alone).10 The onset 
was both early (≤60 days) and late (≥180 days) during treat-
ment. The specific onset of bleeding in patients with squa-
mous NSCLC was not reported. In the phase 2/3 BR.24 study 
of cediranib or placebo plus C/P, the incidence of grade ≥3 
bleeding events (3% versus 1%, respectively) and hemopty-
sis (2% versus 0%) were greater in patients receiving cedira-
nib.12 However, the tumor histology of these patients was not 
reported. In contrast, in the ESCAPE study, which evaluated 
sorafenib with or without C/P, sorafenib treatment was not 
associated with an increased risk of bleeding.13 Although the 
incidence of fatal bleeding events was greater among patients 
with squamous compared with nonsquamous histology (2% 
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Patients With  Median OS Time,
n Events, n Months (95% CI)
Motesanib + C/P 182 145 11.1 (9.0–12.8)
Placebo + C/P 178 150 10.7 (9.4–12.1)
Hazard ratio (95% CI) 0.89 (0.71–1.12)
P 0.3306
,emiTSFPnaideM htiWstneitaP
n Events, n Months (95% CI)
Motesanib + C/P 182 114 4.9 (4.2–5.6)
Placebo + C/P 178 121 5.1 (4.4–5.6)
Hazard ratio (95% CI) 0.85 (0.65–1.11)
P 0.2294
FIGURE 2.  Overall survival time (A) and 
progression-free survival time (B) among 
patients who received motesanib 125 mg 
once daily plus carboplatin/paclitaxel or 
placebo plus carboplatin/paclitaxel in 
all randomized patients with squamous 
histology.
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versus 0.3%, respectively), it was similar among patients with 
squamous NSCLC who received sorafenib and those who did 
not (2% in each arm). Finally, in a phase 2 study of vandetanib 
plus C/P for the treatment of advanced NSCLC, grade ≥3 
hemoptysis did not occur in the vandetanib arm.11 It has been 
speculated that the increased risk of bleeding may be a con-
sequence of the greater likelihood of squamous tumors to be 
centrally located and/or to cavitate, suggesting that tumor his-
tology is an important factor to consider in the toxicity evalu-
ation of any new drug being developed in this setting.10 Data 
collected from the patient cohort with squamous histology in 
the MONET1 study did not yield sufficient information to 
investigate this hypothesis further. Interestingly, in a phase 3 
study of the vascular disrupting agent ASA404 in patients with 
squamous or nonsquamous NSCLC, treatment with ASA404 
plus C/P was not associated with increased toxicity compared 
with placebo plus paclitaxel (efficacy outcomes were also not 
improved).32 The biologic mechanisms by which VEGF path-
way inhibitors might induce bleeding remain uncertain. It is 
possible that differences in mechanisms of action and effects 
on tumor blood vessels of different VEGF pathway inhibitors 
might influence the incidence of bleeding across studies.
Although there was no evidence of improved OS, PFS, 
or ORR among patients in Arm A versus Arm B, the results 
must be interpreted with caution because treatment duration 
with motesanib in the squamous cohort was relatively short: 
the median was 2.2 months (67 days), compared with 4.1 
months for patients in the nonsquamous cohort.21 The short 
treatment duration was largely a consequence of the deci-
sion to terminate motesanib treatment among patients with 
squamous histology, but early discontinuation due to toxicity 
may also have contributed. Clearly, the limited exposure to 
motesanib confounds evaluation of its antitumor activity in 
squamous NSCLC and makes comparison with results from 
other studies of VEGF pathway inhibitors in this setting dif-
ficult.11–13 A study evaluating C/P plus vandetanib or placebo 
demonstrated a trend toward improved PFS (HR, 0.76; 95% 
CI, 0.32–1.82), but not OS (HR, 1.40; 95% CI, 0.54–3.60) 
among patients with squamous histology who received vande-
tanib.11 Similarly, PFS was longer (HR, 0.66) among patients 
with squamous histology who received cediranib in the BR.24 
study, but there was no statistically significant difference from 
the overall study cohort.12 By contrast, in the ESCAPE study, 
OS was shorter (8.9 versus 13.7 months, respectively; HR, 
1.85; 95% CI, 1.22–2.81) and nonspecific toxicity rates were 
higher among patients with squamous NSCLC who received 
sorafenib compared with placebo.13 Therefore, patients 
with squamous histology who were originally included in 
the NExUS trial of gemcitabine/cisplatin with or without 
sorafenib were discontinued as a precaution.14 Considering 
the inconsistent evidence of improvements from these stud-
ies (only 18% to 24% [n = 42–223] of enrolled patients had 
squamous histology), it is unclear whether a positive risk-ben-
efit profile can be achieved with VEGF pathway inhibitors in 
combination with chemotherapy in squamous NSCLC.
Currently available data raise questions about the future 
of these agents as treatment options for patients with squa-
mous histology. The data indicate an increased risk of bleed-
ing, at least with some VEGF pathway inhibitors, and this 
consequently compromises the ability to evaluate efficacy. 
If additional studies of VEGF pathway inhibitors are con-
ducted, patients with squamous histology should be evalu-
ated separately from those with nonsquamous histology. A 
recent study found that elevated VEGF was associated with 
better outcomes in patients with squamous histology, but not 
adenocarcinoma histology.33 These results suggest a different 
relationship between squamous tumors and angiogenic path-
ways that might explain the differing response to VEGF inhi-
bition in patients with squamous and nonsquamous histology. 
Because they represent one of the largest cohorts of patients 
with squamous histology reported to date, the results from the 
MONET1 squamous cohort provides an important benchmark 
for future studies. Alternative approaches for adding VEGF 
pathway inhibitors to standard-of-care regimens should also 
be considered. For example, the open-label BRIDGE study, 
which enrolled only patients with squamous NSCLC, evalu-
ated C/P chemotherapy with bevacizumab introduced at the 
third chemotherapy cycle and continued as maintenance ther-
apy after the sixth cycle. One of 31 treated patients had severe 
pulmonary hemorrhage.34
In summary, results from patients with squamous his-
tology enrolled in the MONET1 study found higher early 
mortality and unacceptable toxicity among patients receiving 
motesanib. The results suggest that, in patients with NSCLC, 
tumor histology plays an important role in determining not 
only efficacy, but also toxicity. The results represent one of 
TABLE 4.  Tumor Response per RECISTa
Arm A  
Motesanib + C/P 
(n = 182)
Arm B  
Placebo + C/P 
(n = 178)
Patients with measurable disease at  
baseline, n (%)
178 (98) 177 (99)
Response assessment, n (%)
  Confirmed CR 0 (0) 1 (<1)
  Confirmed PR 67 (38) 61 (34)
  SDb 70 (39) 79 (45)
Progressive disease 15 (8) 20 (11)
  Not donec 26 (15) 16 (9)
Confirmed objective response  
(CR or PR), n (%)
67 (38) 62 (35)
  Difference, % (95% CI) 2.6 (−7.4 to 12.6)
  p valued 0.7362
Responders with measurable  
disease at baseline, n (%)
67 (38) 62 (35)
Duration of response, mo (95% CI) 7.2 (4.8–9.1) 4.4 (4.2–5.6)
C/P, carboplatin/paclitaxel; CR, complete response; PR, partial response; SD, stable 
disease; RECIST, Response Evaluation Criteria in Solid Tumors; CI, confidence interval.
aAssessed by investigators per RECIST version 1.0. The analysis set included all 
randomized patients who had squamous histology. The denominator for all response 
categories was the number of patients with measurable disease at baseline.
bPatients with an assessment of PR or CR not confirmed ≥4 weeks later were 
classified as having SD.
cPatients for whom imaging was not performed at the scheduled assessment of 
response.
dFrom Cochran-Mantel-Haenszel test stratified by the randomization stratification 
factors.
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the largest datasets describing squamous NSCLC in a clini-
cal study and provide an important benchmark of outcomes 
in squamous NSCLC that may inform the development and 
interpretation of future studies.
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